Last reviewed · How we verify
NCT05150834
Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines
trial testing This is observational study in Microbiome in 53 participants. Status unknown.
16 July 2021
Quick facts
| Lead sponsor | Korea University Guro Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 53 |
| Start date | 25 February 2021 |
| Primary completion | 16 July 2021 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- This is observational study
Conditions studied
- Microbiome — all drugs for Microbiome →
- Vaccine — all drugs for Vaccine →
- Covid-19 — all drugs for Covid-19 →
- SARS-CoV-2 — all drugs for SARS-CoV-2 →
Sponsor
Korea University Guro Hospital
Who can join
18 and older, any sex, with Microbiome or Vaccine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Vaccination is the best way to mitigate the coronavirus disease 2019 (COVID-19) pandemic, but the vaccine immunogenicity may be quite variable from person to person. There is increasing evidence suggesting that the gut microbiome is a major determinant of vaccine immunogenicity. Thus, the investigators investigated the relationship between gut microbiota and humoral immune response after COVID-19 vaccination.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05150834
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of This is observational study
Trials testing the same drug.
- NCT06312774 — Feasibility of Proteomics in Chronic Lung Disease With Sarcopenia · not yet recruiting
Other recruiting trials for Microbiome
Currently open trials in the same condition.
- NCT07501455 — Comparison of the Effects of Oral Hygiene Regimens on Clinical, Immunomodulatory, and Microbial Outcomes and Oral Tolera · NA · recruiting
- NCT07439718 — The Effects of an Oral Nutritional Intervention on the Small Intestine Microbiome · NA · recruiting
- NCT07209007 — Dynamics of Dysbiosis in the Skin and Gut Microbiome of Burn Patients · recruiting
- NCT06778083 — STI Prophylaxis and Emergence of Antimicrobial Resistance · recruiting
- NCT06606119 — The Role of Brain-Bone Marrow-Gut Interaction Following Major Trauma · recruiting
Other Korea University Guro Hospital trials
Trials by the same sponsor.
- NCT07009769 — AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy · completed
- NCT06752733 — Cardiac Stunning After Electrical Cardioversion · active not recruiting
- NCT06202690 — SP Robotic Versus VATS Anatomical Pulmonary Resection for Patients With NSCLC · NA · not yet recruiting
- NCT06889259 — Efficacy and Safety of CBT on Tinnitus · NA · completed
- NCT05704621 — Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Mai · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05150834 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Korea University Guro Hospital
- Last refreshed: 9 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05150834.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing